期刊文献+

肺动脉高压分子机制的研究进展 被引量:3

下载PDF
导出
摘要 肺动脉高压(pulmonary arterial hypertension,PAH)是以肺血管阻力进行性升高,和右心功能进行性衰竭为主要特征的病理过程,是很多心、肺血管疾病发生、发展的重要病理生理基础.最近的临床实验、基础研究中发现[1],一些细胞因子、信号通路、基因表达、离子通道功能等发生改变后,血管内大量异常增殖反应,导致了不可逆性肺血管的重构,肺动脉高压形成的结局,而且它们之间并不是独立的,有很多的相互作用.这里,就其分子机制综述如下.
出处 《心肺血管病杂志》 CAS 2014年第1期130-132,共3页 Journal of Cardiovascular and Pulmonary Diseases
  • 相关文献

参考文献34

  • 1Rabinovitch M. Molecular pathogenesis of pulmonary arterial hy- pertension. J Clin Invest. 2012, 122 : 4306.
  • 2Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension ( Gene(i) PPH1 </i) ) Is Caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Gen- et, 2000, 67: 737-744.
  • 3Maehado RD, Aldred MA, James V, et al. Mutations of the TGF - 13 type II receptor BMPR2 in pulmonary arterial hypertension. Hum Murat, 2006, 27: 121-132.
  • 4Roberts KE, MeElroy JJ, Wong WP, et al. BMPP,2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J, 2004, 24: 371-374.
  • 5魏美丽,韩波,王来城,孙瑾.先天性心脏病并肺动脉高压患儿骨形成蛋白Ⅱ型受体基因新突变[J].实用儿科临床杂志,2012,27(13):994-996. 被引量:2
  • 6Jiang BH, Zheng JZ, Leung SW, et al. Transactivation and in- hibitory domains of hypoxia-induciblefactor let. Modulation oftranscriptional activity by oxygentension. J Biol Chem, 1997, 272 : 19253-19260.
  • 7Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-in- ducible factor lalpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene, 2001,20:5779-5788.
  • 8Semenza GL. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp Phys- iol, 2006, 91: 803-806.
  • 9MacLean MR. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action7. Trends Pharmacol Sci, 1999,20:490-495.
  • 10Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the hu- man cardiovascular system. Pharmacol Ther,2006,111:674-706.

二级参考文献43

共引文献71

同被引文献18

  • 1GalieN,Rubin LJ,Hoeper M,et al.Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan(EARLY study):a double-blind,randomized controlled trial.Lancet,2008,371:2093-2100.
  • 2Galie N,Beghetti M,Gatzoulis MA,et al.Bosentan therapy in patients with Eisenmenger syndrome:a multicenter,doubleblind,randomized,placebo-controlled study.Circulation,2006,114:48-54.
  • 3GalièN1,Hoeper MM,Humbert M,et al.Guidelines for the diagnosis and treatment of pulmonary hypertension:the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology(ESC)and the european respiratory society(ERS),endorsed by the International society of heart and lung transplantation(ISHLT).Eur Heart J,2009,30:2493-537.
  • 4Corretti MC,Anderson TJ,Benjamin EJ,et al.Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery:a report of the International Brachial Artery Reactivity Task Force.J Am Coll Cardiol,2002,16,39:257-65.
  • 5Therrien J,Rambihar S,Newman B,et al.Eisenmenger syndrome and atrial septal defect:nature or nurture?Can J Cardiol,2006,22:1133-6.
  • 6Strange G,Keogh A,Williams T,et al.Bosentan therapy in patients with pulmonary arterial hypertension:the relationship between improvements in 6 minute walk distance and quality of life.Respirology,2008,13:674-682.
  • 7Chen SJ,Chen YF,Meng QC,et al.Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.J Appl Physiol,1995,79:2122-2131.
  • 8Sfikakis PP,Papamichael C,Stamatelopoulos KS,et al.Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.Arthritis Rheum,2007,56:1985-1993.
  • 9张颖,刘双,杨京华.肺动脉高压诊断及分类[J].心肺血管病杂志,2008,27(3):191-192. 被引量:15
  • 10陈明,方少兵,刘衍斌,李桔莲,程起,周小英,相广财.实时三维超声心动图左心房容积指数评价2型糖尿病患者左心房功能[J].中国医药导报,2013,10(19):109-111. 被引量:3

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部